Shares of Neurocrine Biosciences NBIX decreased 13.34% in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were up 7.78% year over year to $0.97, which beat the estimate of ($0.06).
Revenue of $258,500,000 rose by 16.39% year over year, which missed the estimate of $283,040,000.
Guidance
Neurocrine Biosciences hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Nov 09, 2020
Time: 04:30 PM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1046/38078
Technicals
52-week high: $136.26
52-week low: $72.14
Price action over last quarter: down 25.52%
Company Overview
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
